期刊文献+

HIV-1 pol抗原HLA-A*0201限制性低亲和性CTL表位预测及改造分析 被引量:1

Prediction and modification analysis of low-affinity HLA-A0201 restricted CTL epitopes derived from HIV-1 pol antigen
下载PDF
导出
摘要 目的:初步筛选HIV-1pol抗原的HLA-A*0201限制性低亲和性CTL表位,预测并初步鉴定修饰后的表位与HLA-A*0201之间亲和性的变化。方法:采用超基序、蛋白酶解、HLA结合力等预测相结合的办法筛选HLA-A*0201限制性低亲和性CTL表位,通过氨基酸置换适当修饰,并以T2细胞检测HLA-A*0201分子与肽的亲和力和稳定性来评价修饰后表位。结果:筛选出的低亲和性CTL候选表位,经修饰后与HLA-A*0201之间的亲和性均有不同程度的提高。其中,YVSLSFPQI(pol52-60Y1),YVSQIIEQL(pol673-681Y1),YIQKETWEA(pol548-556Y1)HLA-A*0201呈高亲和力结合,同时肽-HLA-A*0201复合物半数解离时间(Dissociation Complex50,DC50)均大于8h。结论:预测的pol抗原表位经过修饰可能会成为潜在的HLA-A*0201限制性表位。 AIM: To screen the possible HLA-A * 0201 restricted low-affinity CTL epitopes derived from HIV-1 pol antigen and to predict and identify the possible change of the affinity between epitope and the HLA-A * 0201 molecule when the epitope is modified. METHODS: HLA-A * 0201 restricted low-affinity CTL epitopes were predicted by CTL epitope prediction software based on super motif, proteasome cleavage probability, HLA affinity and so on. The candidates were modified acid substitution and analyzed by computer. T2 cells were used to determine the peptide by amino binding affinity and HLA-A * 0201-peptide complex stability. RESULTS: Among the three predicted peptides by softer ware, YVSLSFPQI (pol52-60Y1), YVSQIIEQL pol (673-681Y1), YIQKETWEA ( po1548-556Y1 ) could bind to HLA-A * 0201 with high affinity, and the dissociation time of 50% HLA-A * 0201 peptide complex was over to 8 h. CONCLUSION: Our results suggest that the three predicted peptides, as modification, might be HLA-A * 0201 restricted CTL epitopes.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第4期322-324,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30600527)
关键词 HIV-1 CTL 表位 HIV-1 CTL epitope
  • 相关文献

参考文献9

  • 1Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides base on independent binding of individual peptide side-chains [ J ]. J Immunol, 1994, 152 ( 1 ) : 163 - 175.
  • 2Sparacio S, Zeilfelder U, Pfeiffer T, et al. Membrane fusion between retroviral particles: hostrange extension and vaccine prospects. Virology[J]. Virology, 2000, 271 (2): 248-252.
  • 3Goulder PJ, Rowland Jones SL, McMichael A J, et al. Anti-HIV cellular immunity : recent advances towards vaccine design [ J ]. AIDS, 1999, 13(SupplA) : S121- 136.
  • 4Talwar GP, Diwan M, Razvi F, et al. The impact of new technologies on vaccines[J]. Natl Med J India, 1999, 12(6) : 274 -280.
  • 5Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of gag-specific cytotoxic Tlymphocyte res-ponses during the clinical course of HIV-1 infection : a longitudinal analysis of rapid progressors and long-term asymptomatics [ J ]. J Exp Med, 1995, 181 (4) : 1365 - 1372.
  • 6Rosenberg SA, Yang JC, Schwartzentruber D J, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma[ J]. Nat Med, 1998, 4 (3) : 321 -327.
  • 7Lin Z H, Wu Y Z, Wei YL, et al. A rapid method for quantitative prediction of high affinity CTL epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A * 2.1 [J]. Letters in Peptide Sci, 2003, 10(1) : 15 -23.
  • 8Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A * 0201-associated peptides : implication in the identification of cryptic tumor epitopes [ J ]. Eur J Immunol, 2000, 30 (12) : 3411 - 3421.
  • 9Huartc E, Sarobe P, Lu J, et al. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements[J]. Clin Cancer Res, 2002, 8(7): 2336-2344.

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部